Sandoz Sets Forth On Quest To Raise Its Margins
Executive Summary
Sandoz is set to undergo a transformation in terms of operational efficiency, geographic footprint and portfolio offering in a bid to lift its operating margin from the mid-teens range towards 20%.
You may also be interested in...
Sandoz Will Not Pursue US Advair Rival
Sandoz has decided to discontinue development of its generic version of GlaxoSmithKline’s Advair Diskus respiratory brand, resulting in an impairment charge of $442m.
Slowing Biopharmaceuticals Puts A Dent In Sandoz’ Sales
Slower sales growth by its Biopharmaceuticals unit amid competitive pressures in the US, combined with weakness in its Retail Generics and Anti-Infectives franchises, led Sandoz to report an overall 8% sales slide in the first quarter of this year.
Sandoz Head Francis To Leave Amid Move Towards Autonomy
Sandoz’ drive to greater efficiency and stronger profit margins through a group-wide transformation process has prompted the division’s global head, Richard Francis, to step down.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: